eファーマシーの重要動向、地域別分析、市場予測 2022-2027年

出版:Juniper Research(ジュニパーリサーチ) 出版年月:2022年10月

ePharmacy: Key Trends, Regional Analysis and Market Forecasts 2022-2027
eファーマシーの重要動向、地域別分析、市場予測 2022-2027年

価格 GBP2,990
種別 英文調査報告書

詳細はこちらをご覧ください。

レポート目次  お問合せ・ご注文  価格・納期について

無料サンプル

Juniper Research(ジュニパーリサーチ)ではeファーマシーの利用者が2027年までに世界で10億人に達すると予測しています。

Juniper Research「eファーマシーの重要動向、地域別分析、市場予測 2022-2027年 – ePharmacy: Key Trends, Regional Analysis and Market Forecasts 2022-2027」は世界のeファーマシー(オンライン薬局)を調査し、市場機会、技術、主要促進要因、主要eファーマシーベンダー15社情報に関する分析・解説を行っています。

またeファーマシーの利用者数、eファーマシーの取引数、OTC数、eファーマシー経由での処方箋取引数、eファーマシーの総収益については世界60ヶ国の予測を含む市場データも提供します。

主な掲載内容

  • 市場ダイナミクス
    • 新型コロナウイルス感染症(COVID-19)が与える市場への影響
    • eファーマシーの今後の戦略的方向性と市場展望
    • 規制とデータ共有において留意すべき主な問題点
  • 地域別分析:主要8地域16ヶ国におけるeファーマシーの現在の展開レベルと今後の展望
  • 主な調査結果と戦略的提言
  • 産業予測:eファーマシーの利用者、eファーマシーへの年間支出総額、eファーマシーの総課金収益、eファーマシーの総取引額の予測。OTCおよび処方箋医薬品毎の取引総数と収益。対象地域(8地域)および国(60ヶ国)は下記の通り
    • 北米:カナダ、米国
    • ラテンアメリカ:アルゼンチン、ブラジル、チリ、コロンビア、エクアドル、メキシコ、ペルー、ウルグアイ
    • 西欧:オーストリア、ベルギー、デンマーク、フィンランド、フランス、ドイツ、ギリシャ、アイルランド、イタリア、オランダ、ノルウェー、ポルトガル、スペイン、スウェーデン、スイス、英国
    • 中東欧:クロアチア、チェコ共和国、ハンガリー、ポーランド、ルーマニア、ロシア、トルコ、ウクライナ
    • 極東と中国:中国、香港、日本、韓国
    • インド亜大陸:バングラデシュ、インド、ネパール、パキスタン
    • その他のアジア太平洋地域:オーストラリア、インドネシア、マレーシア、ニュージーランド、フィリピン、シンガポール、タイ、ベトナム
    • アフリカおよび中東:アルジェリア、エジプト、イスラエル、ケニア、クウェート、ナイジェリア、カタール、サウジアラビア、南アフリカ、アラブ首長国連邦
  • Juniper Researchの競合スコアボード:主要15社の特性と能力評価
    • 1mg
    • Amazon Pharmacy
    • Apollo Pharmacy
    • CVS Health
    • DocMorris
    • Express Scripts
    • Giant Eagle Pharmacy
    • Kroger
    • Lloyds Pharmacy
    • Netmeds
    • Optum
    • Rowlands Pharmacy
    • Walgreens Boots Alliance
    • Walmart
    • Well Pharmacy

当レポートは下記疑問への回答につながる情報を提供しています。

  1. 主要市場の動向がeファーマシーへどのような影響を与えるか?
  2. eファーマシーはOTCと処方箋医薬品とどのような違いがあるか?
  3. eファーマシー市場における主要ベンダは?
  4. eファーマシーにとって成長阻害要因となる限界は?
  5. eファーマシーがもっとも成功する地域は?

Report Overview

Juniper Research’s ePharmacy report provides a detailed evaluation of the market, including the adoption of ePharmacy within both developing and established markets. In addition, this report covers market opportunities; providing strategic insights into the technologies and key drivers that are pushing the space forward, and the role of 15 leading ePharmacy vendors across the market.

The research suite also contains a detailed dataset; providing forecasts for 60 countries across a number of different metrics, including the number of ePharmacy users, number of ePharmacy transactions, number of OTC (Over the Counter) and prescription transactions through ePharmacy and total ePharmacy revenue.

This research suite comprises of:

  • Strategy & Forecasts (PDF)
  • 5-year Market Sizing & Forecast Spreadsheet (Excel)
  • 12 Months Access to harvest Online Data Platform

KEY FEATURES

  • Market Dynamics: A strategic analysis of the major drivers, challenges, and innovations shaping the adoption and development of ePharmacy technologies, including the following:
    • COVID-19 impact on the ePharmacy market
    • Future strategic direction and market outlook for ePharmacy
    • Key issues ePharmacy vendors must be aware of surrounding legislation and data sharing
  • Regional Analysis: A regional-level analysis of 16 countries, spanning 8 key regions; covering the current deployment level and future outlook of ePharmacy in each market.
  • Key Takeaways & Strategic Recommendations: Analysis of key development opportunities within ePharmacies, accompanied by key strategic recommendations for stakeholders.
  • Benchmark Industry Forecasts: Includes forecasts for total number of ePharmacy users, total annual spend on ePharmacy, total fee revenue from ePharmacy, total transaction value from ePharmacy. Total number of transactions and revenue split by OTC and prescription medication. This data is split by our 8 key forecast regions and 60 countries:
    • North America:
      • Canada, US
    • Latin America:
      • Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay
    • West Europe:
      • Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK
    • Central & East Europe:
      • Croatia, Czech Republic, Hungary, Poland, Romania, Russia, Turkey, Ukraine
    • Far East & China:
      • China, Hong Kong, Japan, South Korea
    • Indian Subcontinent:
      • Bangladesh, India, Nepal, Pakistan
    • Rest of Asia Pacific:
      • Australia, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam
    • Africa & Middle East:
      • Algeria, Egypt, Israel, Kenya, Kuwait, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates
  • Juniper Research Competitor Leaderboard: Key player capability and capacity assessment for 15 ePharmacy vendors:
    • 1mg
    • Amazon Pharmacy
    • Apollo Pharmacy
    • CVS Health
    • DocMorris
    • Express Scripts
    • Giant Eagle Pharmacy
    • Kroger
    • Lloyds Pharmacy
    • Netmeds
    • Optum
    • Rowlands Pharmacy
    • Walgreens Boots Alliance
    • Walmart
    • Well Pharmacy

KEY QUESTIONS ANSWERED

  1. How will key market trends affect ePharmacy?
  2. How will ePharmacy differ for over-the-counter and prescription medication?
  3. Who are the leading vendors in the ePharmacy market?
  4. What limitations are holding back ePharmacy?
  5. What regions will ePharmacy be most successful in?

COMPANIES REFERENCED

Included in the Juniper Research Competitor Leaderboard: 1mg, Amazon Pharmacy, Apollo Pharmacy, CVS Health, DocMorris, Express Scripts, Giant Eagle, Lloyds Pharmacy, Netmeds, Optum, Rowlands Pharmacy, The Kroger, Walgreens Boots Alliance, Walmart, Well Pharmacy.

Mentioned: Accredo, Adipositas Care, Adobe, Aetna, Bajaj Allianz, Bakers, Berkshire Hathaway, Blue Cross Blue Shield, Braze, CareCentrix, CareContinum, CareZone, Chefaa, City Market Food and Pharmacy, Copps, CuraScriptSD, Deliveroo, Ecrebo, Epic, Evicore Healthcare, Famhealth, FredMeyer, Freedom Fertility Pharmacy, Frys, HasHealth, Haven, HDFC, Horizon, ICICI Bank, Inside Rx, JPMorgan Chase, KiviHealth, Lazada Philippines, Lyf, Mamajan Imaging, Max Bupa, MedAvail, Medbase, Mesmerize, Microsoft, MyMatrixx, NCotably, Novo Nordisk, Omnicell, Onofre, Patanjali, PathCare, PAYBACK, PillPack, Practio, Prime Therapeutics, Raia Drogasil SA, SBI, Shopee Philippines, Signify Health, Target Pharmacies, Tata Digital, TeleClinic, Thyrocare, Verizon, Willons, Yodawy, ZEE5, Zur Rose Group.

DATA & INTERACTIVE FORECAST

Juniper Research’s ePharmacy forecast suite includes:

  • Prescription Medication
  • Over-the-Counter Medication

Metrics including total number of transactions completed through ePharmacy, total annual spend on ePharmacy, total revenue through ePharmacy transactions, total revenue through ePharmacy fees, split by OTC and prescription medication.

Geographical splits: 60 countries
Number of tables: Over 31 tables
Number of datapoints: Over 23,500 datapoints

harvest: Our online data platform, harvest, contains the very latest market data and is updated throughout the year. This is a fully featured platform enabling clients to better understand key data trends and manipulate charts and tables; overlaying different forecasts within the one chart – using the comparison tool. Empower your business with our market intelligence centre, and receive alerts whenever your data is updated.

Interactive Excels (IFxl): Our IFxl tool enables clients to manipulate both forecast data and charts, within an Excel environment, to test their own assumptions using the interactive scenario tool and compare selected markets side by side in customised charts and tables. IFxls greatly increase a client’s ability to both understand a particular market and to integrate their own views into the model.

FORECAST SUMMARY

The number of ePharmacy users will reach 1 billion globally by 2027; increasing from 795 million in 2022, a growth of 28%. The research identified this increase as the culmination of surging adoption resulting from the COVID-19 pandemic, where consumers were unable to leave their homes and turned to receiving medication through ePharmacies. Growth will continue, as vendors focus on retaining and expanding their customer bases through refining the efficiency and simplicity that ePharmacy provides.

  • Consumers will continue to utilise ePharmacies as they realise the benefits it provides them, including affordability of medication, and a wider range of choice compared to bricks-and-mortar pharmacies.
  • ePharmacy growth will be sustained by simplifying the online process. This can be achieved through more widespread acceptance of ePrescriptions; eliminating paper copies of their prescriptions.
  • ePharmacy services will continue to be predominantly utilised for OTC (Over-the-Counter) medication. OTC transactions will reach 8.9 billion globally in 2027, accounting for 64% of total global transaction value. This is compared to 5 billion prescription transactions globally in the same year. Prescription digitisation will lag behind due to consumer concerns around delivery accuracy, timing and missed deliveries. In order to allay these concerns and offset the abundance of illegitimate ePharmacies, real-time tracking and stronger regulations for ePharmacies should be priorities to secure future growth.

レポート構成&価格表

  • 市場動向・戦略・予測レポート(PDF)
    Market trends, strategies and forecasts report (pdf)
  • 市場データ&予測(Excel)
    Market data & forecasts – All topic data and interactivity (xls)
  • 最新データへの12ヶ月アクセス
    harvest market data platform (12 months’ online access)
GBP 2,990

[プレスリリース]
EPHARMACY USERS TO REACH 1 BILLION GLOBALLY BY 2027; CAPITALISING ON COVID-19 SURGE

Hampshire, UK – 10th October 2022: A new study from Juniper Research found that the number of ePharmacy users will reach 1 billion globally by 2027; increasing from 795 million in 2022, a growth of 28%. The research identified this increase as the culmination of surging adoption resulting from the COVID-19 pandemic, where consumers were unable to leave their homes and turned to receiving medication through ePharmacies. Growth will continue, as vendors focus on retaining and expanding their customer bases by refining the efficiency and simplicity that ePharmacy provides.

ePharmacy is where online pharmacies sell medication, including prescriptions, over the Internet, with the ability to deliver straight to the consumer.

Increase in Accessibility of eCommerce Driving Growth

The research predicts that consumers will continue to utilise ePharmacies as they realise the benefits they provide them, including affordability of medication, and a wider range of choice compared to bricks‑and-mortar pharmacies.

Furthermore, the report predicts that ePharmacy growth will be sustained by simplifying the online process. This can be achieved through more widespread acceptance of ePrescriptions; eliminating paper copies of prescriptions.

Research author Cara Malone remarked: “ePharmacy vendors have the ability to further simplify the process through the use of solutions, including consumers receiving their prescribed medication, sorted into daily pouches containing information regarding dosage, date and time to be taken.”

Issues Surrounding Delivery Remain a Barrier

The research anticipates that ePharmacy services will continue to be predominantly utilised for OTC (Over-the-Counter) medication. OTC transactions will reach 8.9 billion globally in 2027; accounting for 64% of total global transaction value. This is compared to 5 billion prescription transactions globally in the same year. Prescription digitisation will lag behind due to consumer concerns around delivery accuracy, timing and missed deliveries. In order to allay these concerns and offset the abundance of illegitimate ePharmacies, real-time tracking and stronger regulations for ePharmacies should be priorities to secure future growth.

Juniper Research provides research and analytical services to the global hi-tech communications sector; providing consultancy, analyst reports, and industry commentary.


目次

Contents

1. Key Takeaways & Strategic Recommendations

1.1 Key Takeaways & Strategic Recommendations ………6
1.2 Strategic Recommendations …………….7

2. Current Status & Future Outlook

2.1 Overview of ePharmacy Ecosystem ………….9
Figure 2.1: Visualisation Showing ePharmacy Stages ……..9
2.1.1 Types of ePharmacy…………….9
i. Digital-only Stores …………..9
ii. Digital Twin of Bricks-and-Mortar…………9
2.1.2 ePrescribing ……………..9
Figure 2.2: Visualisation of ePrescribing………… 10
2.2 Benefits of ePharmacy……………10
2.2.1 Benefits for Consumers…………..10
i. Time Saving ……………..10
ii. Cost Savings ………………10
iii. Efficiency……………..11
iv. Personalisation ……………11
v. Range of Choice……………11
2.2.2 Benefits for Corporations…………..11
i. Time Saving ……………..11
ii. Maximise Profit Margin…………11
Figure 2.3: Visualisation Showing Benefits for Corporates…… 12
iii. Benefits for Governments …………12
2.3 Exploration of Key Market Drivers…………..12
2.4 Limitations………………..13

3. Regional Analysis

3.1 Regional Analysis……………… 16
3.1.1 North America…………….. 16
i. US……………… 16
ii. Canada …………….. 16
3.1.2 Latin America ……………… 17
i. Mexico………………. 17
ii. Brazil……………… 17
3.1.3 West Europe…………….. 18
i. Germany ……………… 18
ii. UK……………….. 18
3.1.4 East & Central Europe ……………. 19
i. Poland ………………. 19
ii. Turkey………………. 19
3.1.5 Far East & China…………….. 20
i. China………………. 20
ii. South Korea ……………… 20
3.1.6 Indian Subcontinent……………. 20
i. India……………….. 20
ii. Pakistan……………. 21
3.1.7 Asia Pacific …………….. 21
i. Australia ……………. 21
ii. Philippines …………….. 21
3.1.8 Africa & Middle East ……………. 22
i. Egypt………………. 22
ii. United Arab Emirates ………….. 22

4. Competitor Leaderboard and Vendor Profiles

Table 4.1: Juniper Research Competitor Leaderboard: ePharmacy Vendors Included & Product Portfolio …………… 26
Figure 4.2: Juniper Research Leaderboard: ePharmacy Vendors …. 27
Table 4.3: Juniper Research Leaderboard: ePharmacy Vendors & Positioning .. 27
Table 4.4: Juniper Research Leaderboard Heatmap: ePharmacy Vendors … 28

4.1 ePharmacy – Vendor Profiles …………….29
4.1.1 1mg ………………..29
i. Corporate Information ………….29
ii. Geographical Spread…………….29
iii. Key Clients and Partnerships ………….29
iv. High-Level of Offerings …………..29
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..29
4.1.2 Amazon Pharmacy …………….30
i. Corporate Information ………….30
Table 4.5: Amazon’s Select Financial Information ($bn), FY2019-2021 (FYE 31st December)………………. 30
ii. Geographical Spread…………….30
iii. Key Clients and Partnerships ………….30
iv. High-Level of Offerings …………..30
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..30
4.1.3 Apollo Pharmacy …………….31
i. Corporate Information ………….31
ii. Geographical Spread…………….31
iii. Key Clients and Partnerships ………….31
iv. High-Level of Offerings …………..31
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..31
4.1.4 CVS Pharmacy………………32
i. Corporate Information…………. 32
Table 4.6: CVS Health Corporation’s Select Financial Information ($bn), FY 2019-2021 (FYE 31st December) ……………32
ii. Geographical Spread …………… 32
iii. Key Clients and Partnerships…………. 32
iv. High-level of Offerings………… 32
v. Juniper Research’s View: Key Strengths & Strategic Development
Opportunities ……………. 33
4.1.5 DocMorris ……………… 33
i. Corporate Information…………. 33
Table 4.7: Zur Rose’s Select Financial Information ($bn), FY 2019-2021 (FYE 31st December)………………..33
ii. Geographical Spread …………… 33
iii. Key Clients and Partnerships…………. 33
iv. High-Level View of Offerings……….. 33
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 34
4.1.6 Express Scripts ……………. 34
i. Corporate Information…………. 34
ii. Geographical Spread …………… 34
iii. Key Clients and Partnerships…………. 34
iv. High-level of Offerings………… 35
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 35
4.1.7 Giant Eagle…………….. 35
i. Corporate Information…………. 35
ii. Geographical Spread …………… 35
iii. Key Clients and Partnerships…………. 35
iv. High-Level of Offerings………….. 36
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 36
4.1.8 Lloyds Pharmacy …………….36
i. Corporate Information ………….36
ii. Geographical Spread…………….36
iii. Key Clients and Partnerships ………….36
iv. High-level of Offerings …………36
Figure 4.8: Visualisation of Lloyds Direct App………… 37
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..37
4.1.9 Netmeds………………37
i. Corporate Information ………….37
ii. Geographical Spread…………….37
iii. Key Clients and Partnerships ………….37
iv. High-level of Offerings …………38
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..38
4.1.10 Optum ……………….38
i. Corporate Information ………….38
ii. Geographical Spread…………….38
iii. Key Clients and Partnerships ………….38
iv. High-Level of Offerings …………..38
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..39
4.1.11 Rowlands Pharmacy …………..39
i. Corporate Information ………….39
ii. Geographical Spread…………….39
iii. Key Clients and Partnerships ………….39
iv. High-Level of Offerings …………..39
Figure 4.9: Rowlands Pharmacy Hey Pharmacist……… 40
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..40
4.1.12 The Kroger ………………40
i. Corporate Information…………. 40
Table 4.10: Kroger’s Select Financial Information ($bn), FY2020-2022 (FYE 31st January)…………………40
ii. Geographical Spread …………… 40
iii. Key Clients and Partnerships…………. 41
iv. High-Level of Offerings………….. 41
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 41
4.1.13 Walgreens Boots Alliance ………….. 41
i. Corporate Information…………. 41
Table 4.11: Walgreens Boots Alliance’s Select Financial Information ($bn),
FY2019-2021 (FYE 30th August) …………….42
ii. Geographical Spread …………… 42
iii. Key Clients and Partnerships…………. 42
iv. High-level of Offerings………… 42
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 42
4.1.14 Walmart ……………. 42
i. Corporate Information…………. 42
Table 4.12: Walmart’s Select Financial Information ($bn), FY 2020-2022 (FYE 31st January)…………………43
ii. Geographical Spread …………… 43
iii. Key Clients and Partnerships…………. 43
iv. High-level of Offerings………… 43
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 43
4.1.15 Well Pharmacy …………….. 43
i. Corporate Information…………. 43
ii. Geographical Spread …………… 44
iii. Key Clients and Partnerships…………. 44
iv. High-level of Offerings………… 44
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..44
Table 4.13: Juniper Research Competitor Leaderboard Scoring Criteria…. 46

5. Market Forecasts

5.1 Introduction………………48
5.1.1 ePharmacy Prescription Forecast Methodology ……48
5.1.2 ePharmacy OTC Forecast Methodology ……..48
Figure 5.1: ePharmacy Prescription Revenue Methodology ……. 49
Figure 5.2: ePharmacy OTC Revenue Methodology……… 50
5.1.3 Total ePharmacy Transactions ………..51
Figure & Table 5.3: Total ePharmacy Transactions (m), Split by 8 Key Regions, 2022-2027………………. 51
Table 5.4: Total ePharmacy Transactions, Split by Prescription and OTC Medication ………………… 51
5.1.4 Total ePharmacy Transaction Value…………52
Figure & Table 5.5: Total ePharmacy Transaction Value ($m), Split by 8 Key Regions, 2022-2027 ……………… 52
Table 5.6: Total ePharmacy Transaction Value, Split by Prescription and OTC Medication ………………… 52
5.1.5 Total ePharmacy Revenue………….54
Figure & Table 5.7: Total ePharmacy Revenue ($m), Split by 8 Key Regions, 2022-2027……………….. 54
Table 5.8: Total ePharmacy Revenue ($m), Split by Prescription and OTC Medication ………………… 54


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com